• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4829407)   Today's Articles (780)
For: Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002;43:65-73. [PMID: 12052631 DOI: 10.1016/s0732-8893(02)00371-1] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Number Cited by Other Article(s)
1
Zhang Y, Yang Y, Meng X, Zhou X, Guo B. Efficient Kilogram-Scale Synthesis of a Novel Oxazolidinone Antibacterial Candidate YG-056SP. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
2
Almeida L, Dhillon-LaBrooy A, Castro CN, Adossa N, Carriche GM, Guderian M, Lippens S, Dennerlein S, Hesse C, Lambrecht BN, Berod L, Schauser L, Blazar BR, Kalesse M, Müller R, Moita LF, Sparwasser T. Ribosome-Targeting Antibiotics Impair T Cell Effector Function and Ameliorate Autoimmunity by Blocking Mitochondrial Protein Synthesis. Immunity 2020;54:68-83.e6. [PMID: 33238133 PMCID: PMC7837214 DOI: 10.1016/j.immuni.2020.11.001] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Revised: 09/16/2020] [Accepted: 11/03/2020] [Indexed: 02/08/2023]
3
Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN. Antimicrobial Resistance Surveillance and New Drug Development. Open Forum Infect Dis 2019;6:S5-S13. [PMID: 30895210 PMCID: PMC6419994 DOI: 10.1093/ofid/ofy345] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
4
Roger C, Roberts JA, Muller L. Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. Clin Pharmacokinet 2018;57:559-575. [PMID: 29063519 DOI: 10.1007/s40262-017-0601-x] [Citation(s) in RCA: 71] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
5
Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H. Linezolid: a promising option in the treatment of Gram-positives. J Antimicrob Chemother 2016;72:354-364. [PMID: 27999068 DOI: 10.1093/jac/dkw450] [Citation(s) in RCA: 108] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]  Open
6
Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR. Successful Treatment and Cerebrospinal Fluid Penetration of Oral Linezolid in a Patient with Coagulase-Negative Staphylococcus Ventriculitis. Ann Pharmacother 2016;40:1451-5. [PMID: 16772405 DOI: 10.1345/aph.1h029] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
7
Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 2014;17:1-12. [PMID: 24880801 DOI: 10.1016/j.drup.2014.04.002] [Citation(s) in RCA: 157] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
8
Tan TQ, Yogev R. Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent. Expert Rev Clin Pharmacol 2014;1:479-89. [DOI: 10.1586/17512433.1.4.479] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
9
Snir N, Meron-Sudai S, Deshmukh AJ, Dekel S, Ofek I. Antimicrobial properties and elution kinetics of linezolid from polymethylmethacrylate. Orthopedics 2013;36:e1412-7. [PMID: 24200446 DOI: 10.3928/01477447-20131021-24] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
10
Moran GJ, Abrahamian FM, LoVecchio F, Talan DA. Acute Bacterial Skin Infections: Developments Since the 2005 Infectious Diseases Society of America (IDSA) Guidelines. J Emerg Med 2013;44:e397-412. [DOI: 10.1016/j.jemermed.2012.11.050] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2012] [Accepted: 11/02/2012] [Indexed: 01/22/2023]
11
Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients. J Clin Pharmacol 2013;49:1071-8. [DOI: 10.1177/0091270009337947] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
12
Moran GJ, Rothman RE, Volturo GA. Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines. Am J Emerg Med 2013;31:602-12. [PMID: 23380120 DOI: 10.1016/j.ajem.2012.12.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Revised: 11/30/2012] [Accepted: 12/02/2012] [Indexed: 01/02/2023]  Open
13
Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist 2012;5:87-102. [PMID: 22787406 PMCID: PMC3392139 DOI: 10.2147/idr.s25890] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]  Open
14
Frei CR, Miller ML, Lewis JS, Lawson KA, Peddaiahgari R, Talbert RL. Retrospective cohort study of hospitalized adults treated with vancomycin or clindamycin for methicillin-resistant Staphylococcus aureus skin infections. Clin Ther 2011;32:2024-9. [PMID: 21118737 DOI: 10.1016/j.clinthera.2010.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2010] [Indexed: 01/22/2023]
15
Dotis J, Iosifidis E, Ioannidou M, Roilides E. Use of linezolid in pediatrics: a critical review. Int J Infect Dis 2010;14:e638-48. [DOI: 10.1016/j.ijid.2009.10.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2009] [Revised: 09/17/2009] [Accepted: 10/15/2009] [Indexed: 11/24/2022]  Open
16
Chen L, Wang JW, Hai L, Wang GM, Wu Y. Design and Synthesis of Novel 5-Acetylthiomethyl Oxazolidinone Analogs. SYNTHETIC COMMUN 2010. [DOI: 10.1080/00397910902756197] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
17
Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD. Zyvox® Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis 2009;65:404-13. [DOI: 10.1016/j.diagmicrobio.2009.10.001] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2009] [Accepted: 10/04/2009] [Indexed: 10/20/2022]
18
Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2009;35:3-12. [PMID: 19900794 DOI: 10.1016/j.ijantimicag.2009.09.013] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2009] [Revised: 09/14/2009] [Accepted: 09/18/2009] [Indexed: 10/20/2022]
19
Wang XJ, Du GJ, Zhao SQ, Yan M, Gu LQ. Synthesis and Antibacterial Activity of a Series of α-Substituted Acetylpiperazinyl Oxazolidinones. Chem Biol Drug Des 2009;74:276-81. [DOI: 10.1111/j.1747-0285.2009.00859.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
20
Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009;64:191-201. [PMID: 19500528 DOI: 10.1016/j.diagmicrobio.2009.03.001] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2009] [Accepted: 03/04/2009] [Indexed: 01/06/2023]
21
Simonsen GS, Bergh K, Bevanger L, Digranes A, Gaustad P, Melby KK, Høiby EA. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of gram-positive cocci from Norway. ACTA ACUST UNITED AC 2009;36:254-8. [PMID: 15198180 DOI: 10.1080/00365540410019570] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
22
Wang XJ, Wu N, Du GJ, Zhao SQ, Yan M, Gu LQ. Synthesis and Antibacterial Activities of Eperezolid Analogs with Glycinyl Substitutions. Arch Pharm (Weinheim) 2009;342:377-85. [DOI: 10.1002/ardp.200800233] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
23
Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2009;62:416-26. [PMID: 19022153 DOI: 10.1016/j.diagmicrobio.2008.10.010] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2008] [Accepted: 10/15/2008] [Indexed: 10/21/2022]
24
Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn Microbiol Infect Dis 2008;60:221-4. [DOI: 10.1016/j.diagmicrobio.2007.08.007] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2007] [Revised: 08/17/2007] [Accepted: 08/20/2007] [Indexed: 11/27/2022]
25
Jones RN, Fritsche TR, Sader HS, Ross JE. Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 2007;59:199-209. [PMID: 17908617 DOI: 10.1016/j.diagmicrobio.2007.06.001] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2007] [Accepted: 06/06/2007] [Indexed: 10/22/2022]
26
Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007;59:173-9. [PMID: 17574788 DOI: 10.1016/j.diagmicrobio.2007.04.006] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2006] [Revised: 04/17/2007] [Accepted: 04/17/2007] [Indexed: 11/26/2022]
27
Kim KH, Bong YJ, Park JK, Shin KJ, Hwang KY, Kim EE. Structural Basis for Glutamate Racemase Inhibition. J Mol Biol 2007;372:434-43. [PMID: 17658548 DOI: 10.1016/j.jmb.2007.05.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2007] [Revised: 04/19/2007] [Accepted: 05/02/2007] [Indexed: 11/24/2022]
28
Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007;59:309-17. [PMID: 17720350 DOI: 10.1016/j.diagmicrobio.2007.06.004] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2007] [Accepted: 06/07/2007] [Indexed: 11/26/2022]
29
Jørgen B, Merckoll P, Melby KK. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area. ACTA ACUST UNITED AC 2007;39:1059-62. [PMID: 17852934 DOI: 10.1080/00365540701466231] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
30
Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents 2007;29:295-301. [PMID: 17239570 DOI: 10.1016/j.ijantimicag.2006.09.025] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2006] [Revised: 09/25/2006] [Accepted: 09/26/2006] [Indexed: 11/25/2022]
31
Drew RH. Emerging Options for Treatment of Invasive, Multidrug-ResistantStaphylococcus aureusInfections. Pharmacotherapy 2007;27:227-49. [PMID: 17253914 DOI: 10.1592/phco.27.2.227] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
32
Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2007;51:1491-3. [PMID: 17210770 PMCID: PMC1855453 DOI: 10.1128/aac.01496-06] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
33
Paget SD, Boggs CM, Foleno BD, Goldschmidt RM, Hlasta DJ, Weidner-Wells MA, Werblood HM, Bush K, Macielag MJ. Antibacterial activity of pyrrolopyridine-substituted oxazolidinones: synthesis and in vitro SAR of various C-5 acetamide replacements. Bioorg Med Chem Lett 2006;16:4537-42. [PMID: 16806921 DOI: 10.1016/j.bmcl.2006.06.023] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Revised: 06/07/2006] [Accepted: 06/08/2006] [Indexed: 11/18/2022]
34
Eliopoulos GM. Enterococci: on the back burner but still simmering. Curr Infect Dis Rep 2006;8:333-6. [PMID: 16934190 DOI: 10.1007/s11908-006-0039-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
35
Potoski BA, Adams J, Clarke L, Shutt K, Linden PK, Baxter C, Pasculle AW, Capitano B, Peleg AY, Szabo D, Paterson DL. Epidemiological Profile of Linezolid‐Resistant Coagulase‐Negative Staphylococci. Clin Infect Dis 2006;43:165-71. [PMID: 16779742 DOI: 10.1086/505114] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2005] [Accepted: 03/20/2006] [Indexed: 11/03/2022]  Open
36
Draghi DC, Sheehan DF, Hogan P, Sahm DF. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis 2006;55:129-33. [PMID: 16542812 DOI: 10.1016/j.diagmicrobio.2006.01.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2005] [Revised: 11/28/2005] [Accepted: 01/03/2006] [Indexed: 10/24/2022]
37
Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2006;49:5024-32. [PMID: 16304168 PMCID: PMC1315934 DOI: 10.1128/aac.49.12.5024-5032.2005] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
38
Finch R. Gram-positive infections: lessons learnt and novel solutions. Clin Microbiol Infect 2006. [DOI: 10.1111/j.1469-0691.2006.01624.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
39
Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2005;57:279-87. [PMID: 16326811 DOI: 10.1093/jac/dki437] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
40
Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol 2005;8:510-7. [PMID: 16098786 DOI: 10.1016/j.mib.2005.07.001] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2005] [Accepted: 07/28/2005] [Indexed: 10/25/2022]
41
Manfredi R, Sabbatani S, Chiodo F. Severe staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: a case report and literature review. ACTA ACUST UNITED AC 2005;37:513-7. [PMID: 16012016 DOI: 10.1080/00365540510036589] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
42
Ciulla TA, Comer GM, Peloquin C, Wheeler J. Human vitreous distribution of linezolid after a single oral dose. Retina 2005;25:619-24. [PMID: 16077360 DOI: 10.1097/00006982-200507000-00013] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
43
Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6. [PMID: 15917519 PMCID: PMC1140485 DOI: 10.1128/aac.49.6.2260-2266.2005] [Citation(s) in RCA: 327] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2004] [Revised: 11/08/2004] [Accepted: 02/04/2005] [Indexed: 02/05/2023]  Open
44
Cook AM, Ramsey CN, Martin CA, Pittman T. Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection. Pediatr Neurosurg 2005;41:102-4. [PMID: 15942282 DOI: 10.1159/000085165] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2004] [Accepted: 11/17/2004] [Indexed: 11/19/2022]
45
Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39:1010-5. [PMID: 15472854 DOI: 10.1086/423841] [Citation(s) in RCA: 203] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2004] [Accepted: 05/13/2004] [Indexed: 11/03/2022]  Open
46
Paget SD, Foleno BD, Boggs CM, Goldschmidt RM, Hlasta DJ, Weidner-Wells MA, Werblood HM, Wira E, Bush K, Macielag MJ. Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. Bioorg Med Chem Lett 2004;13:4173-7. [PMID: 14622996 DOI: 10.1016/j.bmcl.2003.08.031] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
47
Cerdá Zolezzi P, Rubio Calvo MC, Millán L, Goñi P, Canales M, Capilla S, Durán E, Gómez-Lus R. Macrolide resistance phenotypes of commensal viridans group streptococci and Gemella spp. and PCR detection of resistance genes. Int J Antimicrob Agents 2004;23:582-9. [PMID: 15194129 DOI: 10.1016/j.ijantimicag.2003.10.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2003] [Accepted: 10/29/2003] [Indexed: 11/23/2022]
48
Blasi F, Tarsia P, Cosentini R, Valenti V. Newer antibiotics for the treatment of respiratory tract infections. Curr Opin Pulm Med 2004;10:189-96. [PMID: 15071370 DOI: 10.1097/00063198-200405000-00008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
49
Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004;23:113-9. [PMID: 15013035 DOI: 10.1016/j.ijantimicag.2003.11.003] [Citation(s) in RCA: 218] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
50
Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagn Microbiol Infect Dis 2003;47:435-40. [PMID: 14522519 DOI: 10.1016/s0732-8893(03)00114-7] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA